<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04794478</url>
  </required_header>
  <id_info>
    <org_study_id>PTL-903880</org_study_id>
    <nct_id>NCT04794478</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Effectiveness of the Dexcom Continuous Glucose Monitoring (CGM) System</brief_title>
  <official_title>Evaluation of the Safety and Effectiveness of the Dexcom Continuous Glucose Monitoring (CGM) System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DexCom, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DexCom, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the Safety and Effectiveness of the Dexcom Glucose Monitoring (CGM) System&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to establish performance of the Dexcom CGM System (System) in&#xD;
      comparison to a blood glucose comparator method.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2021</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>All systems worn will be blinded. Sensor wear locations will be pre-assigned. All sensor insertions will be performed at the clinic by subjects and/or caregivers.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Dexcom Continuous Glucose Monitoring System Performance</measure>
    <time_frame>10 days</time_frame>
    <description>The Dexcom Continuous Glucose Monitoring (CGM) System performance will be assessed compared to the Yellow Springs Instrument (YSI) comparator venous plasma measurements</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>System Related Adverse Device Effects</measure>
    <time_frame>10 days</time_frame>
    <description>The Dexcom Continuous Glucose Monitoring (CGM) System will be characterized by Adverse Device Effects experienced by study participants</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>CGM Users</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glucose challenge during clinic sessions to assess performance of CGM compared to comparator measurement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dexcom Continuous Glucose Monitoring System</intervention_name>
    <description>Dexcom Continuous Glucose Monitoring System</description>
    <arm_group_label>CGM Users</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages 2 or older&#xD;
&#xD;
          -  Diagnosis of Type 1 diabetes or Type 2 diabetes&#xD;
&#xD;
          -  Willing to wear the required number of Systems for the total duration of study wear&#xD;
&#xD;
          -  Willing to participate in Clinic Session(s) during study wear&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of extensive skin changes/diseases at sensor wear site(s) that preclude&#xD;
             wearing the sensor(s) on skin&#xD;
&#xD;
          -  Known allergy to medical-grade adhesives&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Hematocrit outside specification&#xD;
&#xD;
          -  â‰¥ 18 years of age:&#xD;
&#xD;
               -  Male: 36.0%;&#xD;
&#xD;
               -  Female: 33.0%;&#xD;
&#xD;
          -  13-17 years of age: 35.0%;&#xD;
&#xD;
          -  7 years - 12 years of age: 32.0%;&#xD;
&#xD;
          -  End stage renal disease and currently managed by dialysis or anticipating initiating&#xD;
             dialysis during the study wear period&#xD;
&#xD;
          -  Required or scheduled to have a Magnetic Resonance Imaging (MRI) scan, Computed&#xD;
             Tomography (CT) scan, or diathermy during the study wear period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stayce Beck, PhD, MPH</last_name>
    <phone>858-203-6454</phone>
    <email>stayce.beck@dexcom.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathleen Hurst</last_name>
    <phone>858-875-9802</phone>
    <email>khurst1@dexcom.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ProSciento</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AMCR Institute</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sansum Diabetes Research Institute</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Clinical Research</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>82404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc. (CTT)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diabetes &amp; Glandular Disease Clinic, P.A.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endeavor Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Research</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UVA Center for Diabetes Technology</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

